{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:34:38Z","timestamp":1792629278911,"version":"4.5.0"},"reference-count":36,"publisher":"Korean College of Neuropsychopharmacology","issue":"1","license":[{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["www.cpn.or.kr"],"crossmark-restriction":true},"short-container-title":["Clin Psychopharmacol Neurosci"],"published-print":{"date-parts":[[2025,2,28]]},"DOI":"10.9758\/cpn.24.1253","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T02:26:43Z","timestamp":1731464803000},"page":"2-14","update-policy":"https:\/\/doi.org\/10.9758\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Xanomeline-trospium (Cobenfy\n                    <sup>TM<\/sup>\n                    ) for Schizophrenia: A Review of the Literature"],"prefix":"10.9758","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5758-4698","authenticated-orcid":false,"given":"Colin M.","family":"Smith","sequence":"first","affiliation":[{"name":"Department of Behavioral Health, Phoenix Indian Medical Center, Indian Health Service, Phoenix, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2941-5224","authenticated-orcid":false,"given":"Morgan Santalucia","family":"Augustine","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Duke University Hospital, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4448-4558","authenticated-orcid":false,"given":"Jessica","family":"Dorrough","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, UNC Health Rex Hospital, Raleigh, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7075-5771","authenticated-orcid":false,"given":"Steven T.","family":"Szabo","sequence":"additional","affiliation":[{"name":"PsychFarm, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e4r\u00e4","family":"Shadaram","sequence":"additional","affiliation":[{"name":"Department of Behavioral Health, Phoenix Indian Medical Center, Indian Health Service, Phoenix, AZ, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth O.G.","family":"Hoffman","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Division of Hospital Medicine, University of Michigan, Ann Arbor, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6904-2466","authenticated-orcid":false,"given":"Andrew","family":"Muzyk","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Campbell University College of Pharmacy and Health Sciences, Buies Creek, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4713","published-online":{"date-parts":[[2024,11,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-023-02138-4"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.154.4.475"},{"key":"ref3","unstructured":"Ban TA<italic>. Fifty years chlorpromazine: a historical perspective. Neuropsychiatr Dis Treat 2007;3:495-500<\/italic>."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2017.09.027"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/0706743717718167"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31135-3"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.177901"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119889296"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.06091591"},{"key":"ref10","unstructured":"United States Food and Drug Administration (FDA)<italic>. FDA approves drug with new mechanism of action for treatment of schizophrenia [Internet]. FDA; 2024 [cited at 2024 Oct 9]. <a target=\"_blank\" href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-drug-new-mechanism-action-treatment-schizophrenia\">https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-drug-new-mechanism-action-treatment-schizophrenia<\/a><\/italic>."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001924"},{"key":"ref12","unstructured":"Vanderah TW<italic>. Katzung's basic & clinical pharmacology. In: Vanderah TW, editor. 16th ed. McGraw Hill;2024<\/italic>."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2013.00055"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.08050769"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.21101083"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2022.09.006"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2020.112989"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2007.09.009"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S406371"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2021.11.032"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2008.12.020"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.090134"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2018.04.010"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017015"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s41537-022-00320-1"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.21m14316"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-02254-9"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02190-6"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2024.0785"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852924001445"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852924001901"},{"key":"ref32","unstructured":"Citrome L, Neugebauer NM, Meli AA, Kando J<italic>. KarXT (xanomeline and trospium) for the treatment of schizophrenia: number needed to treat, number needed to harm, and likelihood to be helped or harmed. In: American Society of Clinical Psychopharmacology Annual Meeting. 2024 May 30<\/italic>."},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.nsa.2024.104220"},{"key":"ref34","unstructured":"Claxton A, Konis G, Kaul I, Brannan SK, Marcus R<italic>. Long-term metabolic outcomes associated with KarXT (xanomeline and trospium): interim results from pooled, long-term safety studies EMERGENT-4 and EMERGENT-5. In: Annual Congress of the Schizophrenia International Research Society. 2024 Apr 3-7<\/italic>."},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2017.16121358"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Hamina A, Taipale H, Lieslehto J, L\u00e4hteenvuo M, Tanskanen A, Mittendorfer-Rutz E, <italic>et al<\/italic><italic>. Comparative effectiveness of antipsychotics in patients with schizophrenia spectrum Disorder. JAMA Netw Open 2024;7:e2438358<\/italic>.","DOI":"10.1001\/jamanetworkopen.2024.38358"}],"container-title":["Clinical Psychopharmacology and Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pdf.medrang.co.kr\/CPN2\/2025\/023\/cpn023-01-02.pdf","content-type":"unspecified","content-version":"tdm","intended-application":"text-mining"},{"URL":"https:\/\/pdf.medrang.co.kr\/CPN2\/2025\/023\/cpn023-01-02.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T02:07:23Z","timestamp":1739844443000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.cpn.or.kr\/journal\/view.html?doi=10.9758\/cpn.24.1253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2,28]]}},"alternative-id":["10.9758\/cpn.24.1253"],"URL":"https:\/\/doi.org\/10.9758\/cpn.24.1253","relation":{},"ISSN":["1738-1088","2093-4327"],"issn-type":[{"value":"1738-1088","type":"print"},{"value":"2093-4327","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,13]]},"assertion":[{"value":"http:\/\/www.cpn.or.kr\/journal\/view.html?doi=10.9758\/cpn.24.1253","URL":"http:\/\/www.cpn.or.kr\/journal\/view.html?doi=10.9758\/cpn.24.1253","name":"the_journal","label":"Clinical Psychopharmacology and Neuroscience","group":{"name":"multiple_resolution","label":"Full text available at:"}},{"value":"2024-10-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-13","order":2,"name":"published","label":"Online First","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}},{"value":"\u00a9 2025 The","name":"copyright","label":"Copyright","group":{"name":"Copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http:\/\/creativecommons.org\/licenses\/by-nc\/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.","name":"license","label":"License","explanation":{"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},"group":{"name":"Copyright_and_licensing","label":"Copyright and Licensing"}}]}}